BMY – Bristol-Myers Squibb Company – Fundamental analysis, financial statements, key ratios, and fair value analysis

Bristol-Myers Squibb Company

Healthcare
Drug Manufacturers – Major
46.89
1.77
3.92%
68.98
45.12
Stock Current Price
Change
Change %
52 Week High
52 Week Low

Financial Ratios

Earnings per Share (EPS)0.87
EPS Estimate Currrent Qtr0.84
Book Value Per Share8.36
Market Cap 77 Billion
PE Ratio 56.2
Dividend Yield3.2780333

Stock Yield

Stock Return 7 Days4.47%
Stock Return 15 Days0.04%
Stock Return 30 Days -4.39%
Stock Return 3 Months-18.89%
Stock Return One Year-15.84%
Stock Return 3 Years-14.12%

Stock Technical Analysis

Relative Strengh Index (14)26.01
Average True Range (14)1.92
Momentum (14)-8.32
Simple Moving Average (14) -8.32
Time Series Forecast (14)49.64
Time Series Forecast (30) 52.4

Stock News

NewsSourcePublished
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for CelgeneYahoo Finance01/06/2019 23:15
Can Bristol-Myers Squibb’s Balance Sheet Handle The Celgene Acquisition?Seeking Alpha01/06/2019 16:46
Bristol-Meyers Squibb Acquisition Of Celgene Is BrilliantSeeking Alpha01/06/2019 16:33
All the Pre-JPM News Healthcare Investors Need to KnowYahoo Finance01/06/2019 15:00
The Week Ahead In Biotech: Conferences, Clinical TrialsYahoo Finance01/06/2019 14:16
Bristol-Myers Squibb to Participate in the 37th Annual J.P. Morgan Healthcare ConferenceYahoo Finance01/05/2019 16:07
[$$] The Muscle Morgan Stanley Flexed in the $74 Billion Bristol-Myers DealYahoo Finance01/05/2019 00:27
AbbVie (ABBV) Inks Immunotherapy Deal with Private BiotechYahoo Finance01/04/2019 23:09
Johns Hopkins, Bristol-Myers must face $1 bln syphilis infections suitYahoo Finance01/04/2019 22:32
Bristol To Become Top 5 Pharma — And Other Fallout From Celgene TakeoverYahoo Finance01/04/2019 21:24
Bristol-Myers Buys Celgene: Smart Plan Or A Rush To Action?Seeking Alpha01/04/2019 16:16
Stock Market Rally Extends On Fed Chairman Powell, Jobs; Apple, Tesla, Delta Disappoint; Bristol-Myers Buys Celgene: Weekly ReviewYahoo Finance01/04/2019 21:06
Candel Therapeutics Completes $28.7 Million Series B FinancingYahoo Finance01/04/2019 19:33
What to Expect from BMY’s Celgene AcquisitionYahoo Finance01/04/2019 18:35
Manufacturing, Apple, & Jobs: This Week’s Top Market StoriesYahoo Finance01/04/2019 18:31
Biotechs lead broad market advance, XBI up 5%Seeking Alpha01/04/2019 13:11
How Bristol-Myers Squibb Stands NowYahoo Finance01/04/2019 17:05

Financial Statements

index2014201520162017
Revenue16 Billion17 Billion19 Billion21 Billion
Cost of Revenue4 Billion4 Billion5 Billion6 Billion
Gross Profit12 Billion13 Billion14 Billion15 Billion
Gross Margin (%)75.24%76.39%74.54%70.80%
Selling General and Administrative Expense5 Billion5 Billion5 Billion5 Billion
Other operating expenses5 Billion6 Billion4 Billion5 Billion
Earning Before Interest and Taxes EBIT2 Billion2 Billion6 Billion5 Billion
EBIT/Operating Margin (%)14.84%12.14%30.19%24.85%
Interest Expense0000
Other non-operating expenses/income0000
Earnings before Tax2 Billion2 Billion6 Billion5 Billion
Income Tax Expense352 Million446 Million1 Billion4 Billion
Net Income2 Billion2 Billion4 Billion1 Billion
Net Margin (%)12.62%9.45%22.94%4.85%
Earnings per share from operating income0.9797071.38170.4965698.4051
Earnings per Diluted Share1.20.932.650.61
Dividends per Basic Common Share1.451.491.141.56
Payout ratio0.8275860.6241612.324560.391026
Weighted average number of shares outstanding2 Billion2 Billion2 Billion2 Billion
index2017 Q42018 Q12018 Q22018 Q3
Revenue5 Billion5 Billion6 Billion6 Billion
Cost of Revenue2 Billion2 Billion2 Billion2 Billion
Gross Profit4 Billion4 Billion4 Billion4 Billion
Gross Margin (%)69.30%69.50%71.51%71.04%
Selling General and Administrative Expense1 Billion980 Million1 Billion1 Billion
Other operating expenses2 Billion859 Million2 Billion783 Million
Earning Before Interest and Taxes EBIT699 Million2 Billion508 Million2 Billion
EBIT/Operating Margin (%)12.83%34.08%8.91%37.88%
Interest Expense0000
Other non-operating expenses/income0000
Earnings before Tax699 Million2 Billion508 Million2 Billion
Income Tax Expense3 Billion284 Million135 Million255 Million
Net Income-2 Billion1 Billion373 Million2 Billion
Net Margin (%)-0.00%28.62%6.54%33.40%
Earnings per share from operating income0.2129491.308925.921440.977707
Earnings per Diluted Share-10.910.231.16
Dividends per Basic Common Share0.390.40.40.4
Payout ratio-42.2750.5752.9
Weighted average number of shares outstanding2 Billion2 Billion2 Billion2 Billion
index2014201520162017
Cash and Equivalents6 Billion2 Billion4 Billion5 Billion
Trade and Non Trade Receivables3 Billion4 Billion6 Billion6 Billion
Inventory2 Billion1 Billion1 Billion1 Billion
Other current assets15 Billion7 Billion11 Billion13 Billion
Current Assets15 Billion10 Billion14 Billion15 Billion
Total Non-Current Assets19 Billion21 Billion20 Billion19 Billion
Total Assets34 Billion32 Billion34 Billion34 Billion
Trade and Non Trade Payables2 Billion2 Billion2 Billion2 Billion
Other current liabilities6 Billion6 Billion7 Billion7 Billion
Current Liabilities8 Billion8 Billion9 Billion10 Billion
Liabilities Non Current10 Billion9 Billion9 Billion12 Billion
Accumulated Retained Earnings Deficit33 Billion32 Billion34 Billion31 Billion
Shareholder’s equity other-18 Billion-17 Billion-17 Billion-19 Billion
Shareholders Equity15 Billion14 Billion16 Billion12 Billion
Noncontrolling interests17 Billion16 Billion18 Billion19 Billion
Total Assets34 Billion32 Billion34 Billion34 Billion
index2017 Q42018 Q12018 Q22018 Q3
Cash and Equivalents5 Billion5 Billion5 Billion5 Billion
Trade and Non Trade Receivables6 Billion6 Billion6 Billion6 Billion
Inventory1 Billion1 Billion1 Billion1 Billion
Other current assets13 Billion13 Billion12 Billion13 Billion
Current Assets15 Billion15 Billion14 Billion15 Billion
Total Non-Current Assets19 Billion18 Billion19 Billion19 Billion
Total Assets34 Billion33 Billion33 Billion34 Billion
Trade and Non Trade Payables2 Billion2 Billion2 Billion2 Billion
Other current liabilities7 Billion8 Billion8 Billion8 Billion
Current Liabilities10 Billion10 Billion10 Billion10 Billion
Liabilities Non Current12 Billion11 Billion10 Billion10 Billion
Accumulated Retained Earnings Deficit31 Billion32 Billion32 Billion33 Billion
Shareholder’s equity other-19 Billion-20 Billion-20 Billion-20 Billion
Shareholders Equity12 Billion13 Billion12 Billion14 Billion
Noncontrolling interests19 Billion19 Billion20 Billion19 Billion
Total Assets34 Billion33 Billion33 Billion34 Billion
index2014201520162017
Net Cash Flow from Operations3 Billion2 Billion3 Billion5 Billion
Capital Expenditure-526 Million-820 Million-1 Billion-1 Billion
Net Cash Flow from Investing1 Billion-2 Billion1 Billion-66 Million
Net Cash Flow from Financing-2 Billion-4 Billion-3 Billion-4 Billion
Cash and Equivalents6 Billion2 Billion4 Billion5 Billion
index2017 Q42018 Q12018 Q22018 Q3
Net Cash Flow from Operations1 Billion1 Billion1 Billion1 Billion
Capital Expenditure-254 Million-239 Million-198 Million-224 Million
Net Cash Flow from Investing1 Billion-43 Million-348 Million-147 Million
Net Cash Flow from Financing-1 Billion-1 Billion-1 Billion-720 Million
Cash and Equivalents5 Billion5 Billion5 Billion5 Billion

Stock Price History

table